The Japanese drugmaker aims to more than double oncology revenue to above ¥2.3 trillion by 2030 and become one of the world's top five oncology players by 2035.
Daiichi Sankyo says its underlying business remains strong despite a one‑time expense and conservative earnings guidance that came in below market expectations.…
